Thursday, 3 April 2014

PRESTIGE study: Goserelin given every 12 vs. 4 weeks in premenopausal women with ER-positive advanced breast cancer

Non-inferiority of goserelin 10.8 mg given every 12 weeks over 3.6 mg administered every 4 weeks has been demonstrated in premenopausal breast cancer patients with oestrogen receptor (ER)-positive tumours. Suppression of serum oestradiol to postmenopausal level was also confirmed with goserelin given every 12 weeks, according to the results of study presented by Dr Kim HJ of the ASAN Medical Center, Seoul, Korea at 9th European Breast Cancer Conference (EBCC-9) held in Glasgow, Scotland from 19 to 21 March 2014. Read more here.

No comments:

Post a Comment